Key Highlights

  • Vectus Biosystems (ASX:VBS) said the US Food and Drug Administration granted its request for a pre-IND Type B meeting.
  • The interaction concerns its proposed program for VB0004 in idiopathic pulmonary fibrosis.
  • Vectus appointed a US regulatory agent to prepare submissions and manage communications with the agency.
  • September-quarter operating cash outflow totalled AUD 309,000, with cash at AUD 410,000 at quarter end.

Vectus Biosystems (ASX:VBS) is an Australian clinical-stage biotechnology company developing therapies for fibrotic diseases. Its 29 October 2026 Quarterly Report covered discussions with the US Food and Drug Administration about the proposed development of VB0004 for idiopathic pulmonary fibrosis. The company also reported its September cash position and a research tax refund received in October.

Written feedback on the proposed VB0004 program

The US regulator granted Vectus’s request for a Type B interaction ahead of a proposed Investigational New Drug application. In this case, the agency was due to respond in writing. In its October filing, Vectus said it expected those responses by mid-November 2026. The company intended to use the feedback in its planning for the next stages of US clinical and regulatory development. After receiving confirmation of the interaction, Vectus and its US regulatory agent began finalising the materials for submission to the agency. The announced milestone was the grant of the meeting request.

The candidate’s existing development record

VB0004 is an oral investigational compound and the company’s initial development focus is idiopathic pulmonary fibrosis, a progressive lung disease. In describing the drug candidate, Vectus identified it as a vasoactive intestinal peptide mimetic that acts on natriuretic peptide receptor C. The company had completed a Phase Ia study in healthy volunteers. It described the results in terms of safety and pharmacokinetics, which concern how the compound behaves in the body. The program before the US regulator relates to proposed development in the pulmonary fibrosis patient population.

US regulatory agent and planned submissions

Vectus formally engaged a US regulatory affairs agent in July 2026 and designated it as the primary contact for its communications with the FDA. Its remit includes preparing materials and facilitating communication about the pre-IND interaction, an Orphan Drug designation request and a future Investigational New Drug application. The engagement covers VB0004 and may be extended to other candidates as they advance. Separately, Vectus described work on potential therapies for fibrosis affecting the cardiovascular system, kidneys and liver. It also cited an existing licensing agreement for one renal fibrosis asset.

September Cash Flow and October refund

Cash declined from AUD 719,000 at 30 June to AUD 410,000 at 30 September, in line with the reported AUD 309,000 net operating outflow. The quarterly cash flow filing listed AUD 103,000 for Patent and research expenses, AUD 39,000 for staff costs and directors’ fees, AUD 97,000 in corporate overheads and AUD 48,000 in legal and professional fees. It also recorded AUD 32,000 in other operating payments and AUD 10,000 in interest received. The AUD 208,000 FY26 Research and Development cash refund arrived in October, after the reporting date.

Vectus reported that it had reduced staffing and consultant numbers after completing its earlier trial and moved to lower-cost premises. The cash flow appendix estimated 1.33 quarters of funding at its reported September quarter expenditure rate. The company was evaluating ways to meet future Capital requirements, including possible licensing arrangements that could Yield upfront payments if agreements are reached.

The October filing documents a completed early clinical study, a granted pre-IND meeting request and preparations for regulatory feedback. Vectus identified the written US responses as an input for the proposed next stages of the VB0004 program.